Quick Answer
Phathom Pharmaceuticals, Inc. reported Long-Term Debt of $209.09 million for fiscal year 2025.
Phathom Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $209.09M | +3.8% |
| 2024 | $201.41M | +46.1% |
| 2023 | $137.84M | +44.7% |
| 2022 | $95.26M | +6.2% |
| 2021 | $89.67M | +126.2% |
| 2020 | $39.63M | +74.0% |
| 2019 | $22.78M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $207.09M | +17.8% | +1.0% |
| June 30, 2025 | $205.14M | +17.6% | +0.9% |
| March 31, 2025 | $203.25M | +36.4% | +0.9% |
| December 31, 2024 | $201.41M | +46.1% | +14.6% |
| September 30, 2024 | $175.73M | +77.0% | +0.7% |
| June 30, 2024 | $174.42M | +78.3% | +17.0% |
| March 31, 2024 | $149.02M | +54.2% | +8.1% |
| December 31, 2023 | $137.84M | +44.7% | +38.9% |
- Phathom Pharmaceuticals, Inc. showed an increase of +3.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2025 period, Phathom Pharmaceuticals, Inc.’s long-term debt has grown by 818.0% (from $22.78 million to $209.09 million).
- The most recent figure is from Phathom Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: